# Niagen Bioscience, Inc. (NAGE) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Niagen Bioscience, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/NAGE/mda/fy2025/): filed 2026-03-04; accession 0001386570-26-000013 (https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/NAGE/mda/fy2024/): filed 2025-03-04; accession 0001628280-25-009774 (https://www.sec.gov/Archives/edgar/data/1386570/000162828025009774/cdxc-20241231.htm)
- [FY 2023 MD&A](/company/NAGE/mda/fy2023/): filed 2024-03-06; accession 0001628280-24-009380 (https://www.sec.gov/Archives/edgar/data/1386570/000162828024009380/cdxc-20231231.htm)
- [FY 2022 MD&A](/company/NAGE/mda/fy2022/): filed 2023-03-08; accession 0001628280-23-006968 (https://www.sec.gov/Archives/edgar/data/1386570/000162828023006968/cdxc-20221231.htm)
- [FY 2021 MD&A](/company/NAGE/mda/fy2021/): filed 2022-03-14; accession 0001628280-22-006041 (https://www.sec.gov/Archives/edgar/data/1386570/000162828022006041/cdxc-20211231.htm)

Back to /company/NAGE/